이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

2 세 이상의 어린이에서 아edcocitinib라는 약에 대한 장기 연구

2026년 11월 3일 업데이트: Pfizer

아크리 티 닙의 안전성과 효능을 평가하는 3 단계, 다기관, 장기, 오픈 라벨 연구, 2 세 이상의 소아 참가자에게 시행되는 국소 약물이 있거나없는 약물 약물이 중등도에서 중등도의 아토피 성 피부염으로 투여됩니다.

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

연구 개요

상태

모병

개입 / 치료

상세 설명

Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.

연구 유형

중재적

등록 (추정된)

450

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Chihuahua City, 멕시코, 31238
        • 아직 모집하지 않음
        • Servicios Hospitalarios de Mexico S.A. DE C.V.
    • Mexico City
      • Mexico City, Mexico City, 멕시코, 06720
        • 아직 모집하지 않음
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey, Nuevo León, 멕시코, 64718
        • 아직 모집하지 않음
        • Eukarya Pharmasite S.C.
    • Veracruz Ignacio de LA Llave
      • Veracruz, Veracruz Ignacio de LA Llave, 멕시코, 91900
        • 아직 모집하지 않음
        • Arké SMO S.A de C.V
    • Alabama
      • Birmingham, Alabama, 미국, 35244
        • 모병
        • Cahaba Dermatology & Skin Health Center
    • Arkansas
      • North Little Rock, Arkansas, 미국, 72117
        • 모병
        • Arkansas Research Trials
    • California
      • San Diego, California, 미국, 92123
        • 모병
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego, California, 미국, 92123
        • 모병
        • University of California, San Diego/ Rady Children's Hospital - San Diego
    • Florida
      • Jacksonville, Florida, 미국, 32256
        • 모병
        • Solutions Through Advanced Research
    • Idaho
      • Meridian, Idaho, 미국, 83646
        • 모병
        • Ada West Research - Meridian
    • Indiana
      • Indianapolis, Indiana, 미국, 46250
        • 모병
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis, Missouri, 미국, 63104
        • 모병
        • Saint Louis University
    • South Carolina
      • Charleston, South Carolina, 미국, 29425
        • 모병
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Greenville, South Carolina, 미국, 29607
        • 모병
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio, Texas, 미국, 78235
        • 모병
        • Texas Dermatology and Laser Specialists
      • Zaragoza, 스페인, 50009
        • 모병
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela, A Coruña [LA Coruña], 스페인, 15706
        • 모병
        • CHUS - Hospital Clinico Universitario
    • Barcelona
      • Granollers, Barcelona, 스페인, 08402
        • 모병
        • Hospital General de Granollers
      • Fukuoka, 일본, 811-1394
        • 모병
        • Fukuoka National Hospital
      • Fukuoka, 일본, 819-0042
        • 모병
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama, Kanagawa, 일본, 220-6208
        • 모병
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai, Osaka, 일본, 593-8324
        • 모병
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku, Tokyo, 일본, 157-0066
        • 모병
        • Sasamoto Children's Clinic
      • Shanghai, 중국, 200062
        • 모병
        • Shanghai Children's Hospital
      • Shanghai, 중국, 200092
        • 모병
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100045
        • 모병
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen, Guangdong, 중국, 518026
        • 모병
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha, Hunan, 중국, 410007
        • 모병
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, 중국, 330000
        • 아직 모집하지 않음
        • Dermatology Hospital of Jiangxi Province
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310009
        • 모병
        • Hangzhou Third People's Hospital
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, 폴란드, 30-002
        • 모병
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, 폴란드, 20-573
        • 모병
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, 폴란드, 02-625
        • 모병
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, 폴란드, 41-500
        • 모병
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, 폴란드, 90-436
        • 모병
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, 폴란드, 27-400
        • 모병
        • Dermedic Jacek Zdybski
    • Baranya
      • Pécs, Baranya, 헝가리, 7632
        • 모병
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba, Bekes County, 헝가리, 5600
        • 모병
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged, Csongrád-csanád, 헝가리, 6720
        • 아직 모집하지 않음
        • University of Szeged
    • Pest County
      • Budapest, Pest County, 헝가리, 1033
        • 모병
        • Clinexpert Kft.

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria for the Extension Cohort:

1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).

• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.

Inclusion Criteria for the De Novo Cohort:

Age

  1. Children aged 6 to <12 years at the time of informed consent/assent.

    • No contraception methods are required for male participants.

    Disease Characteristics:

  2. Participants who meet all of the following AD criteria:

    • A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
    • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
    • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.

    Other Inclusion Criteria:

  3. Body weight ≥15 kg

Exclusion Criteria for the Extension Cohort:

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

    Prior/Concomitant Therapy:

  2. Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.

  3. Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.

    Diagnostic Assessments:

  4. Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.

  5. Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.

Exclusion Criteria for the De Novo Cohort

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

  2. Have any of the following medical conditions:

    • Infections:

      • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
      • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
      • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
      • Infection with HIV, hepatitis B, and/or hepatitis C
      • Evidence of active TB or inadequately treated latent TB.
    • Skin Conditions:

      - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

    • Other Conditions:

      • Documented history of skeletal dysplasia.
      • Documented history of retinal detachment.
      • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
      • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
      • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
      • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

    Prior/Concomitant Therapy:

  3. Prior treatment with a systemic JAK inhibitor for AD.

  4. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

  5. Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.

    Prior/Concurrent Clinical Study Experience:

  6. Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

    Diagnostic Assessments:

  7. Hepatic and/or renal and/or hematological abnormalities defined as:

    • AST >2 x ULN
    • Hemoglobin <10 g/dL
    • ALT >2 x ULN
    • ANC <1000/mm3
    • Total bilirubin ≥1.5 x ULN
    • ALC <500/mm3
    • eGFR <60 mL/min/1.73 m2
    • Platelets <150,000 /mm3

    Other Exclusion Criteria:

  8. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Extension

Patients who have completed other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

다른 이름들:
  • PF-04965842
실험적: De novo

Patients who have not participated other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

다른 이름들:
  • PF-04965842

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
기간: 0-24 months

The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment.

0-24 months

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Clinically Significant Laboratory Abnormalities
기간: 0-24 months

The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
기간: Baseline, 24 months

Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

Baseline, 24 months
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
기간: 0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
기간: 0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
기간: 0-24 months

Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points.

0-24 months
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
기간: 0-24 months

Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
Percentage of Participants with Flares
기간: 0-24 months

Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
기간: 0-24 months

Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
기간: 0-24 months

Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
기간: 0-24 months

Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
기간: 0-24 months

Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
기간: 0-24 months

Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
기간: 0-24 months

Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
기간: 0-24 months

Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
기간: 0-24 months

Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo.

0-24 months
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
기간: 0-24 months

Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
기간: 0-24 months

For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations.

0-24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Pfizer CT.gov Call Center, Pfizer

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 12월 2일

기본 완료 (추정된)

2032년 2월 22일

연구 완료 (추정된)

2032년 2월 22일

연구 등록 날짜

최초 제출

2025년 1월 29일

QC 기준을 충족하는 최초 제출

2025년 1월 29일

처음 게시됨 (실제)

2025년 2월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다